Ocular Science Appoints Kip Crecca to Its Board of Directors
Crecca, a long-time industry commercialization professional, to supply expertise on medical device sales, production, distribution and customer support.
Ocular Science Medical Advisory Board Expands to 28 Leaders in Ophthalmology and Optometry from Around the Country
Jacqueline Griffiths, MD, with nearly 30 years of experience, is joining a board that establishes strategies to focus on enhanced clinical solutions, products and patient outcomes for Ocular Science and affiliated PCAB-accredited 503A compounding pharmacy, OSRX.
by Gary Wörtz, MD — In my opinion, compounded drops are the closest thing we have seen to the holy grail of postop pharmaceuticals in my career. Not only do compounded drops save patients money, the quality and convenience compared with both brand-name and generic formulations have piqued the interest of both providers and patients.
2019 was an extraordinary year for Ocular Science and our affiliates OSRX and Regenerative Science. We exceeded revenue and commercial goals across the board, thanks largely to an unprecedented surge of growth from OSRX, our 503A ophthalmic compounding pharmacy, which formulates 14 combinations of medications for post-op cataract and LASIK treatment, glaucoma management, myopia control, and soon, presbyopia.
As Profits Rise, Ocular Science Promotes From Within
Ocular Science, which produces and markets ophthalmic formulations for post-op cataract and LASIK procedures, glaucoma management, myopia control and dry eye disease, has promoted Eric Garner to Vice President of Marketing.
ASCRS FDA Committee Member Speaks on Access to Compounded Drugs
During an FDA public meeting this week, Damien Goldberg, MD, a member of the ASCRS FDA Committee, joined with the ophthalmic community and urged the FDA to ensure ophthalmologists have a pathway to obtain compounded drugs for office-use by allowing physicians to obtain small
